Diagnosis, prognosis, and standard treatment of multiple myeloma

Hematology/Oncology Clinics of North America

Volumn 11, Issue 1, 1997, Pages 111-131

  Boccadoro, M ^a   Pileri, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IDARUBICIN; LOMUSTINE; MELPHALAN; MITOXANTRONE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PLASMA CELL; PRIORITY JOURNAL; REVIEW;

EID: 0030967468     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70418-4     Document Type: Article

References (162)

1. F. Aguzzi M.R. Bergami C. Gasparro Occurrence of monoclonal components in general practice: Clinical implications Eur J Haematol 48 1992 192 195
2. R.J. Aitchison I.A.G. Reilly A.G. Morgan N.H. Russell Vincristine, Adriamycin and high dose steroids in myeloma complicated by renal failure Br J Cancer 61 1990 765 766
3. R. Alexanian M.A. Dimopoulos Management of multiple myeloma Semin Hematol 32 1995 20 30
4. R. Alexanian R. Dreicer Chemotherapy for multiple myeloma Cancer 53 1984 583 588
5. R. Alexanian B. Barlogie D. Dixon Renal failure in multiple myeloma. Pathogenesis and prognostic implications Arch Intern Med 150 1990 1693 1695
6. R. Alexanian B. Barlogie S. Tucker VAD-based regimens as primary treatment for multiple myeloma Am J Hematol 33 1990 86 89
7. R. Alexanian A. Haut A. Khan Treatment of multiple myeloma: Combination chemotherapy with different melphalan dose regimens JAMA 208 1969 1680 1685
8. R. Alexanian S. Salmon J. Bonnet Combination therapy for multiple myeloma Cancer 49 1977 2765 2771
9. K.C. Anderson Who benefits from high-dose therapy for multiple myeloma? J Clin Oncol 13 1995 1291 1296
10. M. Attal J.L. Harousseau A.M. Stoppa A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 335 1996 91 97
11. M. Attal F. Huguet D. Schlaifer Intensive combined therapy for previous untreated aggressive myeloma Blood 79 1992 1130 1136
12. H. Back R. Lindblad S. Rodjer Single-dose intravenous melphalan in advanced multiple myeloma Acta Haematol 83 1990 183 187
13. L. Baldini A. Guffanti B.M. Cesana Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy Blood 87 1996 912 918
14. S. Barille M. Collette R. Bataille M. Amiot Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin Blood 86 1995 3151 3159
15. B. Barlogie G. Gahrton Bone marrow transplantation in multiple myeloma Bone Marrow Transplant 7 1991 71 79
16. B. Barlogie R. Alexanian D. Dixon Prognostic implication of tumor cell DNA and RNA content in multiple myeloma Blood 6 1985 338 341
17. B. Barlogie S. Jagannath D. Vesole G. Tricot Autologous and allogeneic transplants for multiple myeloma Semin Hematol 32 1995 31 44
18. B. Barlogie L. Smith R. Alexanian Effective treatment of advanced multiple myeloma refractory to alkylating agents N Engl J Med 310 1984 1353 1356
19. R. Bartl B. Frisch W. Wilmanns Morphology of multiple myloma Malpas J.S. Bergsagel D.E. Kyle R.A. Myeloma: Biology and Management 1995 Oxford University Press New York 82 123
20. R. Bataille The mechanisms of bone lesions in human plasmacytomas Stem Cells (Dayt) 13 suppl 2 1995 40 47
21. R. Bataille M. Boccadoro B. Klein C-reactive protein and serum β2 microglobulin produce a simple and powerful myeloma staging system Blood 80 1992 733 737
22. R. Bataille D. Chappard M. Basle Excessive bone resorption in human plasmacytomas: Direct induction by tumour cells in vivo Br J Haematol 90 1995 721 724
23. R. Bataille J. Chevalier M. Rossi J. Sany Bone scintigraphy in plasma cell myeloma. A prospective study of 70 patients Radiology 145 1982 801 804
24. R. Bataille B.G.M. Durie J. Grenier Serum beta2-microglobulin and survival duration in multiple myeloma. A simple reliable marker for staging Br J Haematol 55 1983 439 447
25. R. Bataille J. Grenier J. Sany Beta-2-microglobulin in myeloma: Optimal use for staging, prognosis and treatment. A prospective study of 160 patients Blood 63 1984 468 476
26. A. Belch W. Shelley D.E. Bergsagel A randomized trial of maintenance vs. no maintenance melphalan and prednisone in responding multiple myeloma patients Br J Cancer 57 1988 94 99
27. W.I. Bensinger C.D. Buckner C. Anasetti Allogeneic bone marrow transplantation for multiple myeloma: An analysis of risk factors on outcome Blood 88 1996 2787 2793
28. D.E. Bergsagel Chemotherapy of myeloma: Drug combinations versus simile agents, an overview, and comments on acute leukaemia in myeloma Hematol Oncol 6 1988 159 166
29. D.E. Bergsagel Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur J Cancer Clin Oncol 25 1989 159 161
30. D.E. Bergsagel A.J. Bailey G.R. Langley The chemotherapy of plasma cell myeloma and the incidence of acute leukemia N Engl J Med 301 1979 743 748
31. D.E. Bergsagel D.H. Cowan R. Hasselback Plasma cell myeloma: Response of melphalan resistant patients to high dose intermittent cyclophosphamide Can Med Assoc J 107 1972 851 855
32. D.E. Bergsagel M. Osawa S.L. Librach Mouse myeloma. A model for studies of cell kinetics Arch Intern Med 135 1975 109 117
33. A. Bianchi L. Montacchini P. Barral CD3-induced T cell activation in the bone marrow of myeloma patients: Major role of CD4+ cells Br J Haematol 90 1995 625 632
34. J. Blade` J. San Miguel A. Alcada A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma Blut 60 1990 319 322
35. J. Blade´ C. Rozman F. Cervantes A new prognostic system for multiple myeloma based on easily available parameters Br J Haematol 72 1989 507 511
36. Blade´ J. San Miguel J.F. M. Fontanillas Survival of multiple mieloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated J Clin Oncol 14 1996 2167 2173
37. M. Boccadoro A. Pileri Cell kinetics of multiple myeloma Hematol Pathol 1 1987 137 142
38. M. Boccadoro A. Pileri Prognostic factors in multiple myeloma Bergsagel D.E. Kyle R.A. Malpas J.S. Myeloma 1995 Oxford Medical Publications New York 251 270
39. M. Boccadoro S. Battaglio P. Omede` Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma Eur J Haematol 47 1991 305 309
40. M. Boccadoro P. Gavarotti G. Fossati Kinetics of circulating lymphocytes in human myeloma Blood 61 1983 812 814
41. M. Boccadoro P. Gavarotti G. Fossati Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy Br J Haematol 58 1984 689 696
42. M. Boccadoro F. Marmont M. Tribalto Multiple myeloma: Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan and prednisone (MP) even in high risk patients J Clin Oncol 9 1991 444 448
43. M. Boccadoro F. Marmont M. Tribalto Early responder myeloma: Kinetic studies identify a patient subgroup characterized by a very poor prognosis J Clin Oncol 7 1989 119 125
44. Boccadoro M, Palumbo A, Argentino C, et al: Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Haematol, in press
45. Boccadoro M. van Acker A. P.F. Conte Monitoring of a long survival myeloma patient Tumori 67 1982 571 573
46. A.G. Bosanquet E.D. Gilby Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma Eur J Cancer Clin Oncol 18 1982 355 362
47. D.C. Case B.J. Lee B.D. Clarkson Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol Am J Med 63 1977 897 903
48. F. Cavagnaro J.M. Lein S. Pavlovsky Comparison of two combination chemotherapy regimens for multiple myeloma: Methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone Cancer Treat Rep 64 1980 73
49. M. Cavo P. Galieni E. Zuffa Prognostic variables and clinical staging in multiple myeloma Blood 74 1989 1774 1780
50. J.A. Child S.M. Crawford D.R. Norfolk Evaluation of serum β2-microglobulin as a prognostic indicator in myelomatosis Br J Cancer 47 1983 111 114
51. Chronic Leukemia-Myeloma Task Force Guidelines for protocol studies of the National Cancer Institute Cancer Treat Rep 4 1973 145 158
52. H.J. Cohen H.R. Silberman K. Tornyos A.A. Bartolucci Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma Blood 63 1984 639 648
53. G. Cook I.M. Franklin A. Iqbal An oral chemotherapy regimen, Z-DEX (Zavedos capsules [idarubicin] and dexamethasone) is effective in the initial therapy of multiple myeloma [abstract] Blood 10 suppl 1 1996 730
54. P. Corradini G. Inghirami M. Astolfi Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias Leukemia 8 1994 758 767
55. P. Corradini M. Ladetto G. Inghirami N- and K-Ras oncogenes in plasma cell dyscrasias Leuk Lymphoma 15 1994 17 20
56. P. Corradini M. Ladetto C. Voena Mutational activation of N- and K-RAS oncogenes in plasma cell dyscrasias Blood 81 1993 2708 2713
57. P. Corradini C. Voena M. Astolfi High dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood harvests, and after autografting Blood 85 1995 1596 1602
58. U. Dianzani A. Pileri M. Boccadoro Activated idiotype-reactive cells in suppressor-cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status Blood 72 1988 1064 1081
59. B. Drewinko R. Alexanian H. Boyer The growth fraction of human myeloma cells Blood 57 1981 333 338
60. B.G.M. Durie Chemotherapy of myeloma. SWOG studies Hematol Oncol 6 1988 141 148
61. B.G.M. Durie S.E. Salmon A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival Cancer 36 1975 842 854
62. B.G.M. Durie S.E. Salmon Multiple myeloma, macroglobulinemia and monoclonal gammopathies Hoffbrand A.V. Brown M.C. Hirsch J. Recent Advances in Haematology 1977 Churchill Livingstone Edinburgh 243 261
63. B.G.M. Durie S.E. Salmon T.E. Moon Pretreatment tumor mass, cells kinetics, and prognosis in multiple myeloma Blood 55 1980 364 372
64. B.G.M. Durie S.E. Salmon T.E. Moon Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma Blood 59 1982 43 51
65. B.G.M. Durie D. Stock-Novack S.E. Salmon Prognostic value of pretreatment serum β2 microglobulin in myeloma: A Southwest Oncology Group Study Blood 75 1990 823 830
66. H. Ehrsson S. Eksborg A. Osteborg Oral melphalan pharmacokinetics-relation to dose in patients with multiple myeloma Med Oncol Tumor Pharmacother 6 1989 151 154
67. J.P. Fermand P. Ravaud S. Chevret High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: Preliminary results of a randomized trial involving 167 patients Stem Cells (Dayt) 13 suppl 2 1995 156 159
68. J.O. Fernberg B.O. Johansson R. Lewensohn H. Mellstedt Oral dosage of melphalan and response to treatment in multiple myeloma Eur J Cancer 26 1990 393 396
69. G.V. Forgeson P. Selby S. Lachani Infused vincristine and Adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients Br J Cancer 58 1988 469 473
70. D. Fuchs A. Hausen G. Reibnegger Neopterin as a marker for activated cell-mediated immunity Immunology Today 9 1988 150 154
71. H. Garenwal B.G.M. Durie R.A. Kyle Serum β2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders J Clin Oncol 2 1984 51 58
72. W. Gassmann H. Pralle T. Haferlach Staging systems for multiple myeloma: A comparison Br J Haematol 59 1985 703 711
73. Y. Gazitt C.C. Reading R. Hoffman Purified CD34+ Lin-Thy+ stem cells do not contain clonal myeloma cells Blood 86 1995 381 389
74. M.A. Gertz L.A. Kalish R.A. Kyle Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study Am J Clin Oncol 18 1995 475 480
75. A.M. Gianni C. Tarella M. Bregni High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma J Clin Oncol 12 1994 503 509
76. P. Gimsing O. Bjerrum E. Brandt Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): A phase III study Br J Haematol 77 1991 73 79
77. J.H. Goldie A.J. Coldman G.A. Gudauskas Rationale for the use of alternating non cross-resistant chemotherapy Cancer Treat Rep 66 1982 439 449
78. M.E. Gore C. Viner M. Meldrum Intensive treatment of multiple myeloma responding to conventional induction chemotherapy Lancet 14 1989 879 882
79. W.M. Gregori M.A. Richard J.S. Malpas Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: An overview of published trials J Clin Oncol 10 1992 334 342
80. P.R. Greipp R.A. Kyle Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and, and smoldering myeloma Blood 62 1983 166 171
81. P.R. Greipp J.A. Katzmann W.M. O'Fallon R.A. Kyle Value of beta2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma Blood 72 1988 219 223
82. P.R. Greipp J.A. Lust W.M. O'Fallon Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma Blood 81 1993 3382 3387
83. G. Grignani P.G. Gobbi R. Formisano A prognostic index for multiple myeloma Br J Haematol 73 1996 1101 1107
84. O.P. Hansen N.T. Clausen A. Drivsholm B. Laursen Phase three study of intermittent 5-drug regimen (VBMCP) versus intermittent three drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis Scand J Haematol 35 1985 518 524
85. Y. Harada M.M. Kawano N. Huang Identification of early plasma cells in peripheral blood and their clinical significance Br J Haematol 92 1996 184 191
86. J.B. Harley T.F. Pajak O.R. McIntyre Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A study of the CALGB Blood 54 1979 13 22
87. M. Hjorth L. Hellquist E. Holmberg Initial treatment in multiple myeloma: No advantage of multidrug chemotherapy over melphalan-prednisone Br J Haematol 74 1990 185 191
88. S. Jagannath B. Barlogie K. Dicke Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors Blood 76 1990 1860 1866
89. W.J. Johnson R.A. Kyle A.A. Pineda Treatment of renal failure associated with multiple myeloma Arch Intern Med 150 1990 863 869
90. M. Kawano T. Hirano T. Matsuda Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma Nature 332 1988 83 85
91. M.M. Kawano M.S. Mahmoud N. Huang High proportions of VLA-5-immature myeloma cells correlated well with poor response to treatment in multiple myeloma Br J Haematol 91 1995 860 864
92. M.M. Kawano K. Mihara T. Tsujimoto A new phenotypic classification of bone marrow plasmacytosis Int J Hematol 61 1996 179 188
93. N. Keldsen O.W. Bjerrum I.M.S. Dahl Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisone (NOP regimen) versus melphalan and prednisolone: A phase III study Eur J Haematol 51 1993 80 85
94. O. Kindahl-Andersen P. Bjiark A. Bondevik Multiple myeloma in central Norway 1981–1982: A randomized clinical trial of 5-drug combination therapy versus standard therapy Scand J Haematol 37 1986 243 248
95. B. Klein Cytokines and cytokines receptors in human multiple myeloma Malpas J.S. Bergsagel D.E. Kyle R.A. Myeloma 1995 Oxford University Press New York 63 81
96. B. Klein Growth factors in the pathogenesis of multiple myeloma Gahrton G. Durie B.G.M. Multiple Myeloma 1996 Arnold London 73 82
97. B. Klein K. Zhang M. Jourdan Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6 Blood 73 1989 517 526
98. B. Klein X.G. Zhang Z.Y. Lu R. Bataille Interleukin-6 in human multiple myeloma Blood 85 1995 863 872
99. R.A. Kyle Long term survival in multiple myeloma N Engl J Med 19 1978 314 318
100. R.A. Kyle Newer approaches to the therapy of multiple myeloma Blood 76 1990 1678 1679
101. R.A. Kyle “Benign” monoclonal gammopathy—after 20–35 years of follow-up Mayo Clin Proc 68 1994 26 36
102. R.A. Kyle C.M. Beard W.M. O'Fallon L.T. Kurland Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945 J Clin Oncol 12 1994 1577 1583
103. M.C. Kyrstsonis G. Dedoussis C. Baxevanis Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM) Br J Haematol 92 1996 420 422
104. J. Latreille B. Barlogie J. Johnston Ploidy and proliferative characteristics in monoclonal gammopathies Blood 59 1982 43 51
105. B.J. Lee G. Sahakian B.D. Clarkson Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone and BCNU Cancer 33 1974 533 536
106. R.M. Lemoli A. Fortuna M.R. Motta Concomitant mobilization of plasma cells and hemopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells Blood 87 1996 1625 1634
107. Z.Y. Lu H. Brailly J. Wijdenes Measurement of whole body interleukin-6 (IL-6) production: Prediction of the efficacy of anti-IL-6 treatments Blood 86 1995 3123 3131
108. H. Ludwig W. Kumpan H. Sinzinger Radiography and bone scintigraphy in multiple myeloma: A comparative analysis Br J Radiol 55 1982 173 181
109. H. Ludwig D.M. Nachbaur E. Fritz Interleukin-6 is a prognostic factor in multiple myeloma Blood 77 1991 2794 2795
110. I.C.M. MacLennan J. Cusick Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis Br J Cancer 52 1985 153 158
111. C.M. MacLennan K. Kelly A. Crockson Results of the MRC myelomatosis trials for patients entered since 1980 Hematol Oncol 6 1988 145 158
112. I.C.M. MacLennan C. Chapman J. Dunn K. Kelly Combined chemotherapy with ABMC versus melphalan for treatment of myelomatosis Lancet 339 1992 200 205
113. M. Massaia A. Bianchi C. Attisano Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of CD3/TCR complex Blood 78 1991 1770 1780
114. P. McLaughlin R. Alexanian Myeloma protein kinetics following chemotherapy Blood 60 1982 851
115. Medical Research Council's Working Party on Leukaemia in Adults Prognostic features in the third MRC myelomatosis trial Br J Cancer 42 1980 831 840
116. G. Merlini Treatment of primary amyloidosis Semin Hematol 32 1995 60 79
117. G.P. Merlini J.G. Waldenstrom S.D. Jayakar A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients Blood 55 1980 1011 1019
118. A. Miguel-Garcia E. Matutes F. Tarin Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy J Clin Pathol 48 1995 835 839
119. J. Moller-Petersen E.B. Schmidt Diagnostic value of the concentration of the M component in initial classification of monoclonal gammopathy Scand J Haematol 36 1986 295 301
120. L.A. Moulopoulos M.A. Dimopoulos R. Alexanian Multiple myeloma: MR patterns of response to treatment Radiology 193 1994 441 446
121. L.A. Moulopoulos M.A. Dimopoulos T.L. Smith Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma J Clin Oncol 13 1995 251 256
122. L.A. Moulopoulos M.A. Dimopoulos D. Weber Magnetic resonance imaging in the staging of solitary plasmocytoma of bone J Clin Oncol 11 1993 1311 1315
123. MRC working party on leukaemia in adults Analysis and management of renal failure in fourth MRC myelomatosis trial Br Med J 288 1984 1411 1416
124. A. Neri L. Baldini D. Trecca P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy Blood 81 1993 128 135
125. A. Neri J.P. Murphy L. Cro Ras oncogene mutation in multiple myeloma J Exp Med 170 1989 1715 1722
126. P. Omede` M. Boccadoro A. Fusaro Multiple myeloma: “Early” plasma cell phenotype identifies patients with aggressive biological and clinical characteristics Br J Haematol 85 1993 504 513
127. E.E. Osgood The survival time of patients with plasmacytic myeloma Cancer Chemother Rep 9 1960 1 10
128. A. Osterborg A. Ahre` M. Bjorkholm Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the myeloma group of central Sweden Acta Oncologica 29 1990 272 731
129. A.A. Osterborg Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III—a randomized study from MGCS Eur J Haematol 43 1989 54 62
130. A. Osterborg H. Ehrsson S. Eksborg Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients Eur J Cancer Clin Oncol 25 1989 899 903
131. A. Paccagnella G. Cartei V. Fosser Treatment of multiple myeloma with M-2 protocol and without maintenance therapy Eur J Cancer Clin Oncol 10 1983 1345 1351
132. M. Palmer A. Belch J. Hanson Dose intensity analysis of melphalan and prednisone in multiple myeloma J Natl Cancer Inst 80 1988 414
133. M. Palmer A. Belch J. Hanson L. Brox Reassessment of the relationship between M-protein decrement and survival in multiple myeloma Br J Cancer 59 1989 110 112
134. Palumbo A, Pileri A, Triolo S, et al: Multicyclic dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant, in press
135. I.P. Palva P. Ahremberg K. Ala-Harja Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone, a randomized multicentre trial Eur J Haematol 38 1987 50 54
136. N.M. Papadopoulos R.J. Elin D.M. Wilson Incidence of gamma-globulin banding in a healthy population by high resolution electrophoresis Clinical Chemistry 28 1982 707 708
137. S. Pavlovsky C. Corrado M.T. Santorelli An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three and five drug combinations J Clin Oncol 6 1988 769 775
138. D. Peest H. Deicher R. Coldeway Induction and maintenance therapy in multiple myeloma: A multicenter trial of MP versus VMCP Eur J Cancer Clin Oncol 24 1988 1061 1067
139. A. Pich F. Marmont L. Chiusa Argyrophilic nucleolar organizer region counts and prognosis in multiple myeloma Br J Haematol 82 1992 681 688
140. A. Pileri M.G. Bernengo M. Boccadoro Early recruitment in the human myeloma cell population after cytostatic treatment Haematologica 61 1976 184 193
141. A. Pileri A. Carmagnola M. Boccadoro Human myeloma: Kinetics of the remission phase Acta Haematol 68 1982 237 240
142. K. Pulkki T.T. Pelliniemi A. Rajamaky Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group Br J Haematol 92 1996 370 374
143. A. Riccardi P.G. Gobbi G. Ucci Changing clinical presentation of multiple myeloma Euro J Cancer 27 1401-5 1991
144. A. Riccardi G. Merlini C. Montecucco Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma Eur J Cancer Clin Oncol 22 1986 787 791
145. A. Riccardi G. Ucci R. Luoni Treatment of multiple myeloma according to the extension of the disease: A prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma Br J Cancer 70 1994 1203 1210
146. S.E. Salmon A. Haut J.D. Bonnet Alternating combination chemotherapy improves survival in multiple myeloma: A Southwest Oncology Group Study J Clin Oncol 1 1983 453 461
147. D. Samson E. Gaminara A. Newland Infusion of vincristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma Lancet 2 1989 882 885
148. San Miguel J.F. R. Garcia-Sanz M.J. Moro A new staging system for multiple myeloma based on the number of S-phase plasma cells Blood 85 1995 448 455
149. J.F. San Miguel M. Gonzalez A. Gascon Lymphoid subsets and prognostic factors in multiple myeloma Br J Haematol 80 1992 305 309
150. J.R. Sawyer J.A. Waldron S. Jagannath B. Barlogie Cytogenetic findings in 200 patients with multiple myeloma Cancer Genet Cytogenet 82 1995 41 49
151. A. Solomon Bence Jones proteins: Malignant or benign? N Engl J Med 306 1982 605 607
152. C. Tarella P. Omede` M. Boccadoro Early disappearance of murine plasmacytoma stem cells in long-term bone marrow culture Leuk Res 16 1992 743 750
153. W.E. Terpstra H.M. Lokhorst F. Blomjous Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma Br J Haematol 82 1992 46 49
154. R. Tertti A. Alanen K. Remes The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine Br J Haematol 91 1995 658 660
155. R. Torra J. Blade A. Cases Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases Br J Haematol 91 1995 854 859
156. M. Tribalto S. Amadori M. Cantonetti Treatment of multiple myeloma: A randomized study of three different regimens Leuk Res 9 1985 1043 1049
157. G. Tricot B. Barlogie S. Jagannath Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities Blood 86 1995 4250 4256
158. van Hoeven K.H. L.I. Reed S.M. Factor Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy Cancer 66 1989 1472 1474
159. F. Wisloff P. Gimsing M. Hedenus Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma Eur J Haematol 48 1992 70 74
160. T.E. Witzig M.A. Gertz J.A. Lust Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma Blood 88 1996 1780 1787
161. J.M. Woolfenden M.J. Pitt B.G.M. Durie T.E. Moon Comparison of bone scintigraphy and radiography in multiple myeloma Radiology 134 1980 723 728
162. M. Zandeki V. Obein F. Bernardi Monoclonal gammopathy of undetermined significance: Chromosome changes are common finding within bone marrow plasma cells Br J Haematol 90 1995 693 696